Pfizer and BioNTech have released some extraordinary findings from a Phase 3 trial involving 46,307 participants, between seven days and six months after a second dose was administered. The vaccine was found to have a 91.3 per cent efficacy rate. These findings line up with the real world data coming out of Israel, which has used the Pfizer vaccine to inoculate its population, and reported several weeks ago that it proved 94 per cent effective in preventing symptomatic illness.
Already a subscriber? Log in
Get 10 issues
for $10
Subscribe to The Spectator Australia today for the next 10 magazine issues, plus full online access, for just $10.
- Delivery of the weekly magazine
- Unlimited access to spectator.com.au and app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in